CHA2DS2-VASC score predicts coronary artery disease progression and mortality after ventricular arrhythmia in patients with implantable cardioverter-defibrillator

Refik Kavsur1,⁎, Marc Ulrich Becher1, Welat Nassan, Alexander Sedaghat, Adem Aksoy, Jan Wilko Schrickel, Georg Nickenig, Vedat Tiyerili

Department of Internal Medicine II, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany

abstract

Aim: The CHA2DS2-VASC score has expanded its use beyond the initial purpose of predicting the risk of stroke in patients with atrial fibrillation. We aimed to investigate the value of the CHA2DS2-VASC score as a risk assessment tool to predict relevant coronary artery disease (CAD) leading to percutaneous coronary intervention (PCI), and all-cause mortality after detected ventricular arrhythmia (VA) in patients with an Implantable Cardioverter-Defibrillator (ICD).

Methods: A total of 183 ICD-patients who underwent coronary angiography after VA were included and classified according to their CHA2DS2-VASC score in a low(1-3), intermediate(4-5) and high(6-8) score group. We evaluated the predictive value of CHA2DS2-VASC score for the presence of relevant CAD leading to percutaneous coronary intervention (PCI), as well as late all-cause mortality.

Results: A total of 60 patients (32.8%) had significant CAD and underwent successful PCI. After adjustment for relevant parameters such as ischemic cardiomyopathy, angina pectoris, left ventricular ejection fraction, CHA2DS2-VASC score remained the only independent predictor of CAD leading to PCI [HR 1.73 (1.07–2.80)]. The Area under curve was 0.64 (0.56–72, p = 0.002). Kaplan-Meier analysis and log-rank showed an increased three-year mortality of ICD-patients with an intermediate or high score after VA (p = 0.003). Multivariate cox-regression analysis revealed that CHA2DS2-VASC score was also independently associated with all-cause mortality following adjustment for clinically relevant variables (HR 2.20, 1.17–4.14).

Conclusions: CHA2DS2-VASC score can be a predictor of CAD leading to PCI in ICD-patients after VA. ICD-Patients with a high score have an increased risk for reduced three-year all-cause mortality after VA.

1. Introduction

Ventricular arrhythmias (VA) are responsible for most cases of sudden cardiac death and are important contributors to mortality and morbidity in patients with coronary artery disease (CAD) [1]. Especially in patients with CAD, VA is a feared complication and accounts for the majority of deaths occurring in the acute phase of an ischemic event. In patients with an Implantable Cardioverter-Defibrillator (ICD), the ICD serves as ‘safety net’ against life threatening arrhythmias and represents an effective tool terminating VA [2]. An ICD interrogation can be performed to detect VA and distinguish between ventricular tachycardia (VT) and ventricular fibrillation (VF) [3]. As VA can be a sentinel marker of acute or chronic myocardial ischemia, coronary angiography is therefore frequently used to rule out the presence of significant coronary artery stenosis and/or myocardial infarction in VA patients [4,5]. The decision for an invasive strategy after VA in ICD-patients can be difficult, especially in ICD-patients who are stable, without symptoms and with preserved functional capacity. The CHA2DS2-VASC score is a pivotal instrument to assess

https://doi.org/10.1016/j.ijcha.2021.100802
2352-9067/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
the risk of developing cardiac thrombo-embolism and to guide anticoagulant therapy in patients with atrial fibrillation (AF) [6]. The score also demonstrated its prognostic ability in predicting death and cardiovascular hospitalizations among patients with or without AF as well as in various cardiovascular conditions e.g. acute coronary syndrome [7–11].

The aim of the current study was to investigate the value of the CHA2DS2-VASC score as a risk assessment tool to predict significant CAD leading to an invasive reperfusion therapy after detected VA in ICD-patients. We also evaluated its predicting ability for all-cause mortality after detected VA.

2. Methods

2.1. Study population

We retrospectively enrolled 183 patients with an ICD who experienced ventricular arrhythmia (VA) leading to a coronary angiography between 2005 and 2018. The selection process was performed as follows: we scanned our electronic hospital information system for ICD patients who got a coronary angiography, with the help of German International Statistical Classification of Diseases. In the resulting patient-list with more than eight thousand patients, we checked manually, if the patient had a VA prior to coronary angiography, and if VA had an impact in the decision-making of the procedure. VA was detected by ICD interrogation at our center, premature ventricular beats were not included. All patients underwent coronary angiography within the next three months after VA detection, followed by percutaneous coronary intervention (PCI) in cases with significant CAD. Eight patients had a non-invasive ischemia testing performed prior to coronary angiography. Patients had provided informed consent for the procedures and all relevant, medically appropriate care that should be provided in emergencies. All data were fully anonymised before access and analysis. ICD implantation was performed for primary (n = 66/183) or secondary prevention (n = 117/183) [12]. Primary prevention was divided into ischemic (n = 25/66) or non-ischemic aetiology (n = 41/66) [dilated cardiomyopathy (n = 40) or hypertrophic obstructive cardiomyopathy (n = 1)]. As for secondary prevention, the majority of patients had an ischemic cardiomyopathy (n = 105/117), while 9/117 patients had a dilated cardiomyopathy, one patient had a hypertrophic obstructive cardiomyopathy, and two patients had none of these. Of ICD-patients with secondary prevention, 39/117 (33%) patients had a cardiac arrest with cardiopulmonary resuscitation prior to ICD implantation.

2.2. CHA2DS2-VASC score

CHA2DS2-VASC score [applied according to current standards [13]] was calculated for each patient by assigning 1 point each for congestive heart failure, history of hypertension, age between 65 and 74 years, diabetes mellitus, vascular disease (coronary artery or peripheral artery disease), female gender and 2 points each for history of stroke/transient ischemic attack or an age of 75 years or older. Patients were categorized in a low, intermediate and high CHA2DS2-VASC score group. For the attribution of points, the low and high score groups should not exceed one-third of the total cohort.

2.3. Study end points and follow-up

Primary endpoint was the presence of relevant CAD which was revealed in the coronary angiography and leading to PCI. Hereby, revascularization was performed in line with European guidelines [14]. Secondary endpoint was defined as all-cause mortality within 3-year follow-up. Patients were scheduled for regular visits for ICD interrogation every three to twelve months. Patients missing these visits were followed-up via a telephone interview.

2.4. Statistical analysis

Statistical analysis was conducted with SPSS Statistics software version 24.0.0.0 (IBM, Armonk, NY, USA). Data are presented as mean ± standard deviation if normally distributed or as median and interquartile range (quartile 1-quartile 3) if not normally distributed. Normal distribution were tested with the use of the Kolmogorov-Smirnov test. For continuous variables Student's t-test or Mann-Whitney U test was used comparing two groups. Differences between more than two groups were compared by ANOVA or the Kruskal–Wallis test. Chi-square test was performed for analysis of categorical variables. The Kaplan–Meier method and the log rank test were used for presenting the survival rate and determine statistical differences. Univariate and multivariate logistic regression analysis was used to derive independent predictors of the primary endpoint. For multivariate analysis, we included parameter which were known to be associated with relevant CAD and/or showed significance in the univariate analysis. Regarding the primary endpoint theses parameters were: history of smoking, ischemic cardiomyopathy, ICD as secondary prevention, left ventricular ejection fraction, renal function, low-density lipoprotein and symptomatic burden. Receiver operating characteristic (ROC) curves were constructed to confirm and compare the predicting ability or parameters. Multivariate Cox regression analysis was performed for independent predictors of 3-year mortality. For the secondary endpoint we focused on known mortality risk factors rather than parameters associated with CAD and included parameters including age, history of smoking, chronic obstructive pulmonary disease, ischemic cardiomyopathy, body-mass-index, left ventricular ejection fraction, renal function and atrial fibrillation. P-value of < 0.05 was considered to be statistically significant.

3. Results

A total of 183 patients with an ICD who underwent coronary angiography after VA were included into final analysis. The mean age of our study cohort was 71 ± 10.5; 21 patients (11.5%) were of female gender; median Left ventricular ejection fraction (LVEF) was 33% (25–44%). Seventy-four patients (40.4%) presented with angina pectoris, 20 (10.9%) had palpitations, 38 (20.8%) showed dizziness, 28 (15.3%) presented with a syncope, and 67 patients (36.6%) had no specific symptoms. VT in VF zone was detected in 71 of 183 (39%) patients. ICD-treatment included shocks in 116 (63%) patients and antitachycardia pacing in 95 (52%) patients. The indication for ICD in this collective was primary prevention in 36% of cases. Ischemic heart disease was present in 71% of patients. Follow-up data were available for 159 (87%) patients, with a mean follow-up duration of 1124 ± 950 days. Therefore 24 patients were not included for analysis of the secondary endpoint.

Of 183 ICD-patients undergoing coronary angiography after VA, a total of 60 patients (32.8%) showed CAD leading to PCI. Median duration of VA-detection until coronary angiography was 3 [1–12] days. All 60 patients undergoing PCI had a history of vascular disease (p < 0.001); 51 of 60 (85%) had a prior diagnosed ischemic cardiomyopathy (p = 0.004). Mean serum concentration of high-density lipoprotein was 41.4 ± 12.4 and 49.9 ± 26.2 mg/dl in patients with PCI and without PCI, respectively (p = 0.049). There was a trend towards increased prevalence of diabetes in patients with PCI (p = 0.057), and atrial fibrillation was tended to
be less frequent in these patients (p = 0.080); Serum concentration of Troponin I and Creatine Kinase MB isoenzyme (CK-MB) tended to be higher in patients undergoing PCI (p = 0.075 & p = 0.086, respectively). There was no significant difference in other traditional cardiovascular risk factors, including family history, age, BMI, hypertension, history of smoking and low-density lipoprotein (LDL). Furthermore, there was no significant difference in the presence of angina pectoris (p = 0.128) or other symptoms.

3.1. CHA2DS2-VASC score of ICD-patients with VA

Patients were classified according to their CHA2DS2-VASC score. Forty-nine patients (27%) had a low score of 1–3, ninety-nine patients (54%) presented with an intermediate score of 4–5, and thirty-five patients (19%) had a high score of 6–8. There was no patient with a score of 0 or 9. Baseline characteristics according to CHA2DS2-VASC score are shown in Table 1. CHA2DS2-VASC score was higher in patients who underwent PCI (p = 0.002). In total, median CHA2DS2-VASC score was 5 [3–5]. Corresponding to the score parameters, patients with a higher score were older, more often female and had more comorbidities, such as vascular disease and diabetes mellitus (Table 1). 25.7% of patients in the high score group had a prior stroke event, compared with 3% and 0% in the intermediate and low score group (p < 0.001). Patients with prior ischemic cardiomyopathy and patients with a previous coronary artery bypass graft (CABG) had a higher score (p = 0.003 & p = 0.018, respectively). A higher score was associated with an increased serum creatinine (p < 0.001), and the presence of symptoms (p = 0.036). Notably, patients in the high score group had lower values of LDL, cholesterol, triglycerides and hemoglobin (Table 1). There was no significant difference in LVEF (p = 0.160), values of Troponin I (p = 0.101) and CK-MB (p = 0.270).

3.2. CHA2DS2-VASC score as predictor of CAD leading to PCI

PCI was performed in 13.3%, 38.4% and 40.0% of patients with a low, intermediate and high CHA2DS2-VASC score (p = 0.016). Using a logistic regression multivariate analysis when adjusting for risk factors, which included ischemic cardiomyopathy, history of smoking, LDL, LVEF, angina pectoris, renal function, NYHA class and indication of ICD, CHA2DS2-VASC score remained as only significant predictor for CAD progression leading to PCI after VA (Table 2). One increase in the CHA2DS2-VASC score was associated with a 1.73-fold (1.07–2.80) increase in the risk of CAD leading to PCI (p = 0.025). The Area under curve (AUC) for the ability of CHA2DS2-VASC score to predict coronary artery occlusion was 0.638 (95% CI 0.557–0.720, p = 0.002). In comparison to the presence of angina pectoris, ischemic cardiomyopathy and troponin I levels, the CHA2DS2-VASC score had a significant and higher AUC (Table 3).

3.3. CHA2DS2-VASC score as predictor of mortality after VA

During 3-year follow-up after coronary angiography mortality occurred in 7%, 20.9% and 36.7% patients with low, intermediate and high CHA2DS2-VASC score. Kaplan-Meier curves and the log-rank test revealed that patients with an intermediate or high CHA2DS2-VASC score had significantly higher incidence of death in comparison to individuals with a low score (p = 0.003) (Fig. 1). In Cox regression multivariable analysis when adjusting for risk factors which included age, body mass index, history of smoking, chronic obstructive pulmonary disease, atrial fibrillation, serum creatinine, ischemic cardiomyopathy and LVEF, the CHA2DS2-VASC score remained a significant predictor for 3-year mortality (HR 2.20, 95% CI 1.17–4.14, p = 0.014) (Table 4). Serum creatinine was also a significant predictor of 3-year mortality (HR 1.38, 95% CI 1.01–1.89, p = 0.044). In univariate analysis, indication for ICD implantation (primary vs secondary prevention) showed no significant association with 3-year mortality (p = 0.515).

4. Discussion

In this study, we investigate the utility of the CHA2DS2-VASC score as an independent predictor of CAD progression leading to PCI after detected VA in ICD-patients. The score could be helpful for the risk stratification, evaluating the use of an invasive coronary angiography after VA. We demonstrate that each 1-point rise in the CHA2DS2-VASC score is correlated with a 1.73-fold increase in the risk of CAD leading to a PCI in ICD-patients after VA. The correlation of this simple score with relevant CAD progression is a new finding. The CHA2DS2-VASC score also correlates significantly with all-cause mortality in these patients – both unadjusted and when adjusted for potential confounders.

VA after acute myocardial ischemia are relatively common [15]. Thus, in patients presenting with acute life-threatening arrhythmia an immediate invasive strategy is recommended [5,16]. Other traditional criteria for coronary angiography are acute heart failure, angina pectoris, electrocardiogram changes and elevated troponin or CK-MB levels. The decision-making for an invasive strategy is also influenced by intermediate-risk criteria such as recent PCI, prior CABG, renal insufficiency and diabetes mellitus [5]. The risk stratification for invasive coronary angiography can be difficult though, if the patient is protected with an ICD which is effective terminating VA [2]. Recurrent VA can be common in these patients and clinically non-apparent. Also, biomarkers such as troponin and CK-MB can be elevated due to ICD-shocks rather than myocardial ischemia [17,18] and therefore might be losing their ability to predict coronary artery stenosis. In this present study, ROC curve analysis revealed no significant ability for troponin or CK-MB to predict PCI after VA (Table 3). We believe that in ICD-patients there is a lack of tools to predict CAD progression and to evaluate invasive diagnostic procedures. In fact, only 32.8% of patients showed a relevant CAD and underwent PCI. Thus, in the majority of patients the risks and costs of coronary angiography could have been avoided. Comparing the differences between patients who underwent PCI and patients who did not undergo PCI, the known cardiovascular risk factors did not show significance, except the history of ischemic cardiomyopathy. Univariate analysis confirmed a predictive ability of ischemic cardiomyopathy which is known to be associated with VA [19]. Although, comparing ischemic cardiomyopathy to the CHA2DS2-VASC score, the CHA2DS2-VASC score had the upper hand in predicting PCI after VA (Table 3). Furthermore, multivariable analysis revealed the CHA2DS2-VASC score as only remaining predictor.

AF was tended to be less frequent in patients who underwent PCI (p = 0.080). Previous studies have shown that in heart failure patients with high CHA2DS2-VASC score mortality rates may be higher in patients without pre-existing AF than in those with pre-existing AF, which can be considered as consistent with our finding despite the different endpoint [11,20]. However, in these studies AF could have been underdiagnosed since it can be silent frequently. In our collective though, most patients had ICD interrogations regularly, which should have reduced the presence of silent AF. The majority of patients with pre-existing AF received oral anticoagulation which might have served protectively against progression of CAD [21].

Of note is that none of the 12 patients with a CHA2DS2-VASC score of less than three points underwent PCI. In further evaluation of the predictive value, ROC analysis revealed a rather moderate AUC which indicates a limitation in the predictive power. However, our aim was to evaluate the CHA2DS2-VASC score as a predictor to use complementary, rather than a diagnostic tool intended to
Table 1
Baseline characteristics according to the CHA2DS2-VASC score.

| CHA2DS2-VASC score category | Low score 1–3n = 49 (27%) | Intermediate score 4–5n = 99 (54%) | High score 6–8n = 35 (19%) | P value |
|-----------------------------|---------------------------|------------------------------------|---------------------------|--------|
| **Clinical characteristics** |                           |                                    |                           |        |
| Age, years (Mean)           | 59 ± 6.8                  | 73 ± 8.2                           | 81 ± 10.6                 | <0.001 |
| BMI, kg/m²                  | 28.4 ± 5.7                | 27.8 ± 4.3                         | 26.1 ± 3.9                | 0.136  |
| Women, n (%)                | 3 (6.1%)                  | 8 (8.1%)                           | 10 (28.6%)                | 0.002  |
| Diabetes                    | 5 (10.2%)                 | 29 (29.3%)                         | 25 (71.4%)                | <0.001 |
| Hypertension                | 47 (95.9%)                | 99 (100%)                          | 35 (100%)                 | 0.063  |
| Prior stroke                | 0                         | 3 (3.0%)                           | 9 (25.7%)                 | <0.001 |
| Smoker                      | 28 (57.1%)                | 43 (43.4%)                         | 13 (37.1%)                | 0.148  |
| COPD                        | 3 (6.1%)                  | 10 (10.1%)                         | 6 (17.1%)                 | 0.261  |
| Vascular disease            | 30 (61.2%)                | 89 (89.9%)                         | 34 (97.1%)                | <0.001 |
| Previous acute coronary syndrom | 9 (18.4%)             | 32 (32.3%)                         | 8 (22.9%)                 | 0.166  |
| Previous CABG               | 5 (10.2%)                 | 31 (31.3%)                         | 10 (28.6%)                | 0.018  |
| Ischemic cardiomyopathy     | 28 (57.1%)                | 70 (70.7%)                         | 32 (91.4%)                | 0.003  |
| Atrial fibrillation         | 5 (10.2%)                 | 19 (19.2%)                         | 7 (20.0%)                 | 0.338  |
| ICD as secondary prevention | 26 (53.1%)                | 66 (66.7%)                         | 25 (71.4%)                | 0.158  |
| LVEF, % (Median)            | 36 (27–53)                | 31 (24–43)                         | 32 (24–42)                | 0.160  |
| **Laboratory assessment**   |                           |                                    |                           |        |
| Serum creatinine, mg/dl     | 1.05 (0.86–1.46)          | 1.32 (1.10–1.69)                   | 1.84 (1.20–2.50)          | <0.001 |
| Potassium, mmol/l           | 4.5 (4.1–4.8)             | 4.4 (4.2–4.8)                      | 4.5 (4.1–4.8)             | 0.719  |
| Troponin I, μg/l            | 0.04 (0.02–0.25)          | 0.06 (0.02–0.38)                   | 0.21 (0.035–1.01)         | 0.101  |
| CK,μl/l                     | 111 (95–183)              | 110 (67–174)                       | 100 (69–159)              | 0.616  |
| CK-MB, μl/l                 | 2.4 (1.13–3.48)           | 2.6 (1.70–4.38)                    | 2.8 (1.60–5.10)           | 0.270  |
| LDL, mg/dl                  | 92 (85–115)               | 98 (76–118)                        | 76 (62–96)                | 0.030  |
| HDL, mg/dl                  | 43 (37–52)                | 44 (37–54)                         | 44 (36–48)                | 0.985  |
| Cholesterol, mg/dl          | 168 ± 48                  | 172 ± 40                           | 140 ± 45                  | 0.035  |
| Triglycerides, mg/dl        | 148 (115–191)             | 150 (113–274)                      | 109 (84–149)              | 0.043  |
| TSH, μU/ml                  | 1.38 (0.93–2.27)          | 1.22 (0.74–2.11)                   | 1.59 (0.56–2.63)          | 0.863  |
| Hemoglobin, mg/l            | 14.5 (13.3–15.1)          | 14.1 (12.7–14.7)                   | 12.5 (10.8–13.7)          | <0.001 |
| **Presenting symptoms**     |                           |                                    |                           |        |
| Angina pectoris, n (%)      | 12 (24.5%)                | 46 (46.5%)                         | 16 (45.7%)                | 0.029  |
| Palpitation                 | 2 (4.1%)                  | 14 (14.1%)                         | 4 (11.4%)                 | 0.181  |
| Dizziness                   | 8 (16.3%)                 | 17 (17.2%)                         | 13 (37.1%)                | 0.029  |
| Syncope                     | 8 (16.3%)                 | 9 (9.1%)                           | 11 (31.4%)                | 0.007  |
| NYHA III/IV                 | 9 (18.4%)                 | 26 (26.3%)                         | 14 (40.0%)                | 0.086  |
| Asymptomatic                | 25 (51.0%)                | 33 (33.3%)                         | 9 (25.7%)                 | 0.036  |
| **Antiarrhythmic medication** |                        |                                    |                           |        |
| Beta-blocker                | 46 (93.9%)                | 92 (92.9%)                         | 32 (94.1%)                | 0.960  |
| Calcium channel blocker     | 6 (12.2%)                 | 5 (5.1%)                           | 1 (8.3%)                  | 0.160  |
| Amiodarone or flecainide    | 24 (49.0%)                | 42 (42.4%)                         | 14 (41.2%)                | 0.704  |

Values are n (%), mean ± SD, or median with interquartile range (quartile 1 to quartile 3); Abb.: BMI = Body mass index; COPD = Chronic obstructive pulmonary disease; CABG = Coronary artery bypass graft; ICD = Implantable cardiac defibrillator; LVEF = Left ventricular ejection fraction; CK = Creatine kinase; CK-MB = Creatine Kinase MB Isoenzyme; LDL = Low-density lipoprotein; HDL = High-density lipoprotein; TSH = Thyroid-stimulating hormone; NYHA = New York Heart Association class.

Table 2
Predictors of percutaneous coronary intervention.

| Univariate Predictors | Multivariate Predictors |
|-----------------------|-------------------------|
| **CHA2DS2-VASC (per unit increase)** | HR (95% CI) | HR (95% CI) |
| Age (per 1 year increase) | 1.81 (1.12–2.91) | 1.73 (1.07–2.80) |
| Female gender | 1.02 (0.99–1.05) | 1.05 (1.02–1.09) |
| Diabetes | 2.0 (0.81–5.11) | 1.59 (0.48–5.22) |
| Prior stroke | 1.87 (0.58–5.37) | 1.59 (0.48–5.22) |
| Congestive Heart Failure | 3.56 (0.43–29.62) | 1.59 (0.48–5.22) |
| Smoker | 0.95 (0.51–1.76) | 1.59 (0.48–5.22) |
| Previous CABG | 1.13 (0.56–2.28) | 1.59 (0.48–5.22) |
| Ischemic cardiomyopathy | 3.16 (1.42–7.02) | 1.59 (0.48–5.22) |
| TSH (per 1 mg/dl increase) | 0.84 (0.60–1.19) | 0.84 (0.60–1.19) |
| LVEF (per 1% increase) | 1.00 (0.99–1.01) | 0.98 (0.94–1.01) |
| BMI (per 1 kg/m² increase) | 0.99 (0.88–1.15) | 0.99 (0.88–1.15) |
| Creatinine (per 1 mg/dl increase) | 1.68 (0.86–3.27) | 1.68 (0.86–3.27) |
| Hemoglobin (per 1 mg/dl increase) | 0.99 (0.85–1.15) | 0.99 (0.85–1.15) |
| Angina pectoris | 1.62 (0.87–3.03) | 1.34 (0.57–3.14) |
| NYHA III/IV | 0.99 (0.49–1.99) | 0.69 (0.25–1.90) |
| No symptoms | 0.65 (0.34–1.25) | 0.196 |

The CHA2DS2–VASC score remained as only independent predictor of the primary endpoint after adjusting for risk factors. Abb.: BMI = Body mass index; CABG = Coronary artery bypass graft; ICD = Implantable cardiac defibrillator; LVEF = Left ventricular ejection fraction; NYHA = New York Heart Association class.
Figure 1. Kaplan-Meier survival curves stratified by CHA2DS2-VASC score for 3-year mortality. Patients with a high score (6–8 points) and patients with an intermediate score (4–5 points) had lower survival than patients in the low score group (1–3 points). * indicates p-Value < 0.05.

### Table 3
Receiver operating characteristic curve analysis.

| Predictor          | AUC   | 95% CI     | p value |
|--------------------|-------|------------|---------|
| CHA2DS2-VASC       | 0.638 | 0.557–0.720| 0.002   |
| Tropinon I         | 0.601 | 0.490–0.711| 0.080   |
| CK-MB              | 0.599 | 0.489–0.709| 0.087   |
| ICM                | 0.604 | 0.520–0.688| 0.023   |

Significant and highest area under curve (AUC) was measured for the CHA2DS2-VASC score to predict coronary artery disease leading to reperfusion therapy. Abb.: CK-MB = Creatine Kinase MB Isoenzyme; ICM = Ischemic cardiomyopathy.

### Table 4
Multivariate predictors of mortality.

| Predictor                | HR (95% CI) | P value |
|--------------------------|-------------|---------|
| CHA2DS2-VASC (per unit increase) | 2.20 (1.17–4.14) | 0.014   |
| Age (per 1 year increase)   | 0.97 (0.90–1.04) | 0.330   |
| Smoker                    | 1.49 (0.53–4.15) | 0.451   |
| COPD                      | 1.54 (0.39–6.12) | 0.540   |
| Ischemic cardiomyopathy   | 0.52 (0.16–1.71) | 0.524   |
| BMI (per 1 kg/m² increase) | 0.99 (0.85–1.06) | 0.950   |
| LVEF (per 1% increase)    | 0.99 (0.95–1.03) | 0.987   |
| Creatinine (per 1 mg/dl increase) | 1.38 (1.01–1.89) | 0.044   |
| Atrial fibrillation       | 2.02 (0.69–5.96) | 0.277   |

The CHA2DS2-VASC score and serum creatinine were independent predictors of 3-year mortality. Abb.: BMI = Body mass index; COPD = Chronic obstructive pulmonary disease; ICM = Implantable cardiac defibrillator; LVEF = Left ventricular ejection fraction.

The CHA2DS2-VASC score is mostly known for its ability to predict the risk of stroke in patients with AF [6]. Beyond this initial use, recent studies have demonstrated its ability predicting death in patients with or without AF and in various cardiovascular conditions [8,9,11]. Studies have shown its prognostic value in patients with acute coronary syndrome [9,22,23]. In the study of Poci et al., patients with a high score had a worse 10-year survival rate after acute coronary syndrome, irrespective of the presence or absence of AF. Consistent with these findings, in the present study, ICD-patients with an intermediate or high CHA2DS2-VASC score had a worse clinical outcome with an elevated all-cause mortality during three-year follow-up after VA (Fig. 1). After adjusting for interactions between the score and known mortality risk factors such as age, chronic obstructive pulmonary disease, body mass index, LVEF, creatinine, AF etc. it remained an independent predictor of mortality (Table 4). Thus, the CHA2DS2-VASC score might serve as a simple tool for risk stratification in patients after VA, irrespective of the presence or absence of AF. The other remaining independent predictor of all-cause mortality after VA was creatinine, which is concordant to recently published data [24]. In 83% of patients, VA (of which 39% were ventricular fibrillation) led to antitachycardia pacing and/or shock by the ICD. Although speculative, mortality rates presumably would have been much higher in this cohort without the pre-existing ICD.

#### 4.1. Study limitation

Limitations of our study are its monocentric and retrospective character. Furthermore, indication for invasive coronary treatment strategy could have differed as it was evaluated by individual cardiologists. However, revascularization therapies were in line with the European guidelines, though [14]. Moreover, evaluation of relevant coronary stenosis was made primarily by visual inspection. However, this procedure represents the clinical all-day scenario.

### 5. Conclusion

The CHA2DS2-VASC score can be used to optimize the risk stratification, evaluating invasive coronary angiography after VA in ICD-patients. Moreover, the CHA2DS2-VASC score predicts a reduced survival rate in ICD-patients who experienced VA. Patients with a high score may require more intense monitoring due to a higher risk for all-cause mortality.

### Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### References

1. D.P. Zipes, H.J.J. Wellens, Sudden Cardiac Death, Circulation 98 (21) (1998) 2334–2351.
2. A.J. Moss, W.J. Hall, D.S. Cannom, J.P. Daubert, S.L. Higgins, H. Klein, et al., Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators, N. Engl. J. Med. 335 (26) (1996) 1933–1940.
3. W.C. Stevenson, R.M. John, Ventricular arrhythmias in patients with implanted defibrillators, Circulation 124 (16) (2011) e411–e414.
4. P.T. Tang, D.H. Do, A. Li, N.G. Boyle, Team Management of the Ventricular Tachycardia Patient, Arrhythm Electrophysiol. Rev. 7 (4) (2018) 238–246.
5. M. Roffi, C. Patrono, J.P. Collet, C. Mueller, M. Valgimigli, F. Andreotti, et al., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC), Eur. Heart J. 37 (3) (2015) 267–315.
6. G.Y. Lijp, R. Nieuwlaat, R. Pisters, D.A. Lane, H.J. Crijns, Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation, Chest 137 (2) (2010) 263–272.
7. G.Y. Lijp, H.J. Lin, K.L. Chien, H.C. Hsu, T.C. Su, M.F. Chen, et al., Comparative assessment of published atrial fibrillation stroke risk stratification schemes for predicting stroke, in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study, Int. J. Cardiol. 168 (1) (2013) 414–419.
8. K. Orvin, A. Levi, U. Landes, T. Bental, A. Sagie, Y. Shapira, et al., Usefulness of the CHA2DS2-VASC Score to Predict Outcome in Patients Who Underwent Transcatheter Aortic Valve Implantation, Ann. J. Cardiol. 121 (2) (2018) 241–248.
9. D. Poci, M. Hartford, T. Karlsson, J. Herlitz, N. Edvardsson, K. Caidahl, Role of the CHADS2 score in acute coronary syndromes: risk of subsequent death or stroke.
in patients with and without atrial fibrillation, Chest 141 (6) (2012) 1431–
1440.
[10] G.V. Naccarelli, M.P. Panaccio, G. Cummins, N. Tu, CHADS2 and CHA2DS2-VASc risk factors to predict first cardiovascular hospitalization among atrial fibrillation/atrial flutter patients, Am. J. Cardiol. 109 (10) (2012) 1526–1533.
[11] A. Yoshihisa, S. Watanabe, Y. Kanno, M. Takiguchi, A. Sato, T. Yokokawa, et al., The CHA2DS2-VASc score as a predictor of high mortality in hospitalized heart failure patients, ESC Heart Fail 3 (4) (2016) 261–269.
[12] S.G. Priori, C. Blomström-Lundqvist, A. Mazzanti, N. Blom, M. Borggreve, J. Camm, et al., ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC), Eur. Heart J. 36 (41) (2015) 2793–2867.
[13] P. Kirchhof, S. Benussi, D. Kotecha, A. Ailsson, D. Atar, B. Casades, et al., ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS, Eur. Heart J. 37 (38) (2016) 2893–2962.
[14] P. Neumann, M. Sousa-Uva, A. Ailsson, F. Afonso, A.P. Banning, U. Benedetto, et al., ESC/EACTS Guidelines on myocardial revascularization, Eur. Heart J. 38 (2) (2017) 87–165.
[15] D.M. Henkel, B.J. Witt, B.J. Gersh, S.J. Jacobsen, R.A. Mevertor, et al., Ventricular arrhythmias after acute myocardial infarction: a 20-year community study, Am. Heart J. 151 (4) (2006) 806–812.
[16] P.J. Scanlon, D.P. Faxon, A.M. Audet, B. Barabell, G.J. Dehmer, R.A. Eagle, et al., ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography), J. Am. Coll. Cardiol. 33 (1999) 1756–82433.
[17] T. Schmut, H. Baum, A. Plewan, D. Neumeier. Effects of implantable cardioverter defibrillator implantation and shock application on biochemical markers of myocardial damage, Clin. Chem. 47 (3) (2001) 459–463.
[18] C. Hasdemir, N. Shah, A.P. Rao, H. Acosta, K. Matsudaara, B.R. Neas, et al., Analysis of troponin I levels after spontaneous implantable cardioverter defibrillator shocks, J. Cardiovasc. Electrophysiol. 13 (2) (2002) 144–150.
[19] J.N. Weiss, K. Nademanee, W.G. Stevenson, B. Singh, Ventricular arrhythmias in ischemic heart disease, Ann. Intern. Med. 114 (9) (1991) 784–797.
[20] L. Melgaard, A. Gorst-Rasmussen, D.A. Lane, L.H. Rasmussen, T.B. Larsen, G.Y. Lip, Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation, JAMA 314 (10) (2015) 1030–1038.
[21] S.S. Anand, S. Yusuf, Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis, JAMA 282 (21) (1999) 2058–2067.
[22] A. Kurtul, S.K. Acikgoz, Validation of the CHA2DS2-VASc Score in Predicting Coronary Atherosclerotic Burden and In-Hospital Mortality in Patients With Acute Coronary Syndrome, Am. J. Cardiol. 120 (1) (2017) 8–14.
[23] A. Kurtul, Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents, Clin. Appl. Thromb. Hemost. 24 (4) (2018) 589–595.
[24] K. Weidner, M. Behnes, T. Schupp, J. Rusnak, L. Reiser, G. Taton, et al., Prognostic impact of chronic kidney disease and renal replacement therapy in ventricular tachyarrhythmias and aborted cardiac arrest, Clin Res Cardiol 108 (6) (2019) 669–682.